How to Compare Options for Cheapest Compounded Semaglutide: A Transparent Evaluation Checklist
Price alone cannot rank these options. Compounded semaglutide is not an FDA-approved product, so the agency does not review it for safety, effectiveness or quality before it is sold, and two listings with very different numbers may not contain the same active ingredient. A workable comparison normalizes the unit, the ingredient, the compounder, and the prescriber first.
Normalize the unit before any number means anything
Quoted figures in this category are not stated on a common basis. Some are per month, some per four weeks, some per vial, some per shipment covering three months. Convert every option into two numbers: cost per month at the starting strength, and cost per month at the strength a patient is likely to be on once titration finishes. A program that publishes only the first of those is describing an opening position rather than a running cost.
Then normalize what sits inside the fee. A figure that covers a clinician review, follow-up contact, refrigerated shipping, and injection supplies is not the same kind of number as a figure covering the preparation by itself. Until the contents of two fees match, ranking them is arbitrary.
Confirm the active ingredient before you compare cost
The FDA has stated that some semaglutide products sold by compounders may be salt forms, and that semaglutide sodium and semaglutide acetate are different active ingredients from those used in the approved drugs. The agency has said it does not have information on whether those salts share the chemical and pharmacologic properties of the approved ingredient, and that it is not aware of any lawful basis for their use in compounding.
That makes ingredient identity the first comparison variable rather than a technicality. A listing can be cheaper because what is in it is not the same substance. Ask for the ingredient exactly as it appears on the label, in writing, before weighing anything else. The same applies to blended preparations that combine semaglutide with other additives, which sit further from the approved product and make cross-seller price differences close to meaningless.
How openly a provider states the ingredient is itself a sorting tool. Some publish very little before signup, while others such as HealthRX post a dedicated compounded semaglutide page that names the preparation and its recurring price, and larger platforms including Ro, Hims and Hers, and Henry Meds disclose their own terms in varying detail. Lining those public pages up against one another tells you more than a single advertised figure, because a program willing to name the substance in the open is the one a state board of pharmacy check can later confirm.
Establish which category of compounder is behind the vial
Federal law splits compounders in two. A pharmacy operating under section 503A of the Federal Food, Drug, and Cosmetic Act compounds against valid patient-specific prescriptions and is overseen day to day by its state board of pharmacy. An outsourcing facility registered under section 503B is subject to current good manufacturing practice requirements and is inspected by the FDA on a risk-based schedule. Neither category yields an approved drug, but the quality obligations are not equivalent, and a price comparison that ignores the category is comparing two different things at once.
The checklist, in the order it saves the most time
| Dimension | What to obtain first | A complete answer | What a gap usually signals |
|---|---|---|---|
| Active ingredient | Ingredient name as labeled | Semaglutide named plainly, salt status confirmed | Vague wording or a salt form |
| Dispensing pharmacy | Pharmacy name and license state | A name that checks out with that state board of pharmacy | No name, or one that does not verify |
| Prescriber | Clinician name and licensure | Licensed review before anything ships | A questionnaire that ends in a shipment |
| Billed unit | Cost per month at each strength | Pricing published across the whole titration path | One low starter figure only |
| Included services | What the fee covers | Consult, follow-up, and shipping stated up front | Additions that appear at checkout |
| Refill terms | Cancellation and minimum term | Terms readable before payment | Terms visible only after purchase |
The field these programs actually sit in
Compounded programs are one tier of a market with several. Approved semaglutide can be obtained through a benefit plan, and the current Wegovy labeling covers both an injection and a tablet. Manufacturer direct channels sell approved product for cash, with NovoCare Pharmacy handling Novo Nordisk products and LillyDirect covering Eli Lilly’s tirzepatide. Telehealth platforms including Ro and Hims and Hers sit between those tiers, and their product mix has shifted more than once. Supervised cash-pay practices, among them Henry Meds and FormBlends, publish one recurring figure covering the clinician relationship and the preparation together, which is what makes them easy to line up against each other and awkward to line up against a copay.
Why a compounded figure can be lower without being suspect
There is no brand list price in that chain, no rebate, and no pharmacy benefit manager applying a formulary. A practice sets one number and works backward from it. That structure genuinely removes cost, but it does not remove the floor underneath it. Sterile preparation, ingredient sourcing, quality testing, refrigerated shipping, licensed pharmacy overhead, and clinician time all cost money in every legitimate version of this supply.
What a number under the floor is telling you
The FDA’s published telehealth warning signs include deep discounts or prices that seem too good to be true, a company claiming its compounded drug is the same as an approved drug, and a company that ships without screening and a prescription from a licensed doctor. The agency has also described fraudulent compounded semaglutide sold in the United States with false label information, including labels naming compounding pharmacies that do not exist and labels naming real pharmacies that did not make the product.
Two supply-side signals sit behind those prices. The FDA established import alert 66-80 to hold GLP-1 active ingredients with potential quality concerns at the border, and it has issued warning letters to companies selling semaglutide labeled for research purposes or not for human consumption directly to consumers with dosing instructions. Neither route carries the costs a licensed chain carries, which is precisely why the attached numbers look attractive.
Frequently asked questions
Does the cheapest listing always contain a salt form?
No, and price cannot settle it either way. Ingredient identity has to be checked directly, and a legitimate program will name the ingredient on request and on the label. What an unusually low figure does is tell you when to check harder rather than tell you what you are buying.
Does a 503B outsourcing facility make the product approved?
No. Registration under section 503B adds current good manufacturing practice requirements and FDA inspection on a risk-based schedule, which is a real quality difference from a 503A pharmacy. It does not make the compounded drug FDA-approved, and the agency still does not review it before marketing.
How should introductory pricing be handled?
Treat it as one line rather than the headline. Work out the first month, the maintenance months, and the twelve-month total separately, then compare those. A program with a higher opening figure and flat maintenance pricing frequently costs less across a year than one built around an aggressive first month.
Can trial results for the approved drug be applied to a compounded version?
Not directly. Trials such as STEP-1 studied a specific approved product at defined doses under supervision. A compounded preparation has not been through that evaluation, so those outcomes describe the approved medicine rather than whatever a given compounder supplies.
Which single check removes the most bad options fastest?
Asking for the dispensing pharmacy’s name and license state, then verifying it with that state’s board of pharmacy. The FDA advises obtaining a prescription and filling it at a state-licensed pharmacy, and sellers working outside that structure usually cannot produce a name that survives the check.
Sources
- FDA, FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- FDA, Compounding and the FDA: Questions and Answers: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- FDA, Human Drug Compounding Laws: https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
- FDA, BeSafeRx: Your Source for Online Pharmacy Information: https://www.fda.gov/drugs/buying-using-medicine-safely/besaferx-your-source-online-pharmacy-information
- FDA, Counterfeit Medicine: https://www.fda.gov/drugs/buying-using-medicine-safely/counterfeit-medicine
- DailyMed, Wegovy labeling: https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=WEGOVY
- Navigating compounded semaglutide: what health care providers need to know. PubMed: https://pubmed.ncbi.nlm.nih.gov/40966636/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity. PubMed: https://pubmed.ncbi.nlm.nih.gov/33567185/
